Karaoğlanoğlu, SelenErdal, HüseyinSönmez, Müge2024-07-292024-07-2920242602-3164https:/dx.doi.org/ 10.14744/ejmi.2023.39651https://hdl.handle.net/20.500.12451/12262Lung cancer is one of the most cancer type with the highest rate of cancer-related deaths in worldwide. Chronic inflammation has been associated with many diseases, including cancer, and the immune inflammatory re- sponse plays an important role in cancer patients. The aim of the study is to investigate the role of whether the pan- immune-inflammation value (PIV) and the systemic inflammatory response index (SIRI) are effective in predicting non- small lung cancer patients. Methods: In this retrospective case-control study, eighty-four patients and 71 healthy controls followed in Ordu State Hospital, Department of Medical Oncology from January 2020- to January 2023 were included. Results: White Blood Cell, Neutrophil, Hemoglobin , RDW, CRP were statistically significant between the study groups (p<0.05). A statistically significant difference was found between SII, SIRI, PIV, NLR, LMR and dNLR indices between the case and healthy subjects (p<0.05). However, there was no significant difference in PLR levels between the groups (p>0.05). Conclusion: We indicated that SIRI and PIV could be novel cost-effective biomarkers and treatment response precur- sors in patients with NSCLC.eninfo:eu-repo/semantics/embargoedAccessNon-small Cell Lung CancerInflammationSystemic Inflammatory Response IndexPan-immune-inflammation ValueArticle81545710.14744/ejmi.2023.39651